Clinical Trial Update: AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

This is a Phase 2 trial update reporting on cediranib (AZD2171) in adults with recurrent glioblastoma multiforme and related brain tumors; the study status is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Cediranib (Cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Status: COMPLETED